# ImmunoPET Targeting Trop-2 in Solid Tumors (68Ga-MY6349)

Source: https://onco.cc/trials/nct06188468/  
OnCo record `nct06188468` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The Xiamen study that first imaged the TROP2 protein in 90 patients with 15 kinds of cancer using a new PET scan.

## Summary

NCT06188468 evaluated the feasibility of 68Ga-MY6349 PET/CT for non-invasive assessment of Trop2 expression across cancer types, with the aim of identifying patients who might benefit from Trop-2-targeted antibody-drug conjugates. Results were published in the Journal of Clinical Investigation in 2024: uptake correlated with Trop2 immunohistochemistry and was higher than FDG in breast, prostate and thyroid cancer.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-04
- Registry id: NCT06188468
- Phase: not-applicable
- Setting: Patients with solid tumours: 68Ga-MY6349 PET/CT compared with standard-of-care imaging (18F-FDG, 68Ga-PSMA or 68Ga-DOTATATE PET/CT)
- Sponsor: The First Affiliated Hospital of Xiamen University
- Enrolled: 90
- Result: Uptake correlated with Trop2 immunohistochemistry; breast cancer SUVmax 7.2 vs 5.4 with FDG.

## Sources

- ClinicalTrials.gov NCT06188468: https://clinicaltrials.gov/study/NCT06188468
- Chen et al., J Clin Invest 2024: https://doi.org/10.1172/jci185408

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- technologies: [TROP2 PET](https://onco.cc/technologies/trop2-pet/)
- targets: [TROP2](https://onco.cc/targets/trop2/)
- drugs: [68Ga-MY6349](https://onco.cc/drugs/ga68-my6349/)
- key papers: [68Ga-MY6349 PET/CT imaging to assess Trop2 expression in multiple types of cancer](https://onco.cc/key-papers/paper-chen-ga68-my6349-jci-2024/)

---
JSON: https://onco.cc/api/v1/entities/nct06188468.json